Onconetix, Inc. (ONCO)

Onconetix is a small biotech company doing business in urology and oncology. It has two main products: Proclarix, a blood test that diagnoses prostate cancer, and ENTADFI, an FDA-approved pill for enlarged prostate. The company’s shares trade on Nasdaq under the ticker ONCO. It was founded in 2018 and is based in Cincinnati, Ohio. The company changed its name from Blue Water Biotech to Onconetix in late 2023 to better reflect its actual business.

The prostate cancer test: Proclarix

Proclarix is a blood test. A man goes to his doctor with concerns about prostate cancer. The doctor does the usual: digital rectal exam, measure PSA level (a marker protein). If the PSA is elevated and the prostate feels enlarged, the next step is often a biopsy — a needle inserted into the prostate to extract tissue samples. Biopsies are uncomfortable. Many men have them done, but the cancer found is slow-growing and not a threat. So we have a problem: the standard workup catches some aggressive cancers (good) but also detects lots of harmless ones, leading to unnecessary procedures and patient anxiety.

Proclarix addresses this gap. It is a protein-based blood test that looks for patterns in the blood — a molecular signature — that indicate significant prostate cancer. The test works in men with normal findings on physical exam, large prostate glands, and PSA levels in the 2 to 10 nanogram-per-millilitre range. This is the grey zone where the need for biopsy is uncertain. Proclarix gives the doctor and patient better information to decide.

The test was originally developed by a European company called Proteomedix and is already approved for sale in the European Union. Onconetix has licensed the U.S. rights from Proteomedix and has a separate agreement with LabCorp, one of America’s largest diagnostic lab networks. Under the deal, LabCorp will develop and run the test as a laboratory-developed test, or LDT. In the U.S., LDTs are regulated by the FDA but do not require traditional drug approval; instead, the company must show analytical validity (the test measures what it claims) and clinical utility (it actually helps doctors and patients make decisions).

Recent clinical data supports the test. A study in Europe followed 371 men with enlarged prostates and elevated PSA. When Proclarix came back negative, only five percent of those men were later found to have significant cancer. That is much better than the alternatives: checking what percentage of PSA is free versus bound (called percent-free PSA) correctly predicted absence of disease in only fourteen percent of cases. A risk calculator used in Europe (ERSPC) did better at twenty percent. So Proclarix outperformed both conventional methods in reducing unnecessary biopsies.

The revenue model is straightforward: the lab charges the ordering physician. The physician bills insurance or the patient. Proclarix generates revenue per test run, with no recurring component. The addressable market is large — millions of men are screened for prostate cancer yearly in the U.S. — but the test’s adoption depends on whether urologists and primary-care doctors trust it and insurers will pay for it.

The enlarged prostate drug: ENTADFI

ENTADFI is a single-pill combination of two old drugs: finasteride and tadalafil. Both treat benign prostatic hyperplasia, a common condition in older men where the prostate gland grows and obstructs urine flow. Symptoms include weak stream, frequency, urgency, and nighttime awakening.

Finasteride is a generic drug that shrank the prostate gland by blocking the hormone that drives growth. Tadalafil is a generic that relaxes the smooth muscle in the prostate and bladder, improving flow and storage. Both have been used separately for twenty-plus years. Doctors prescribe both together when one alone doesn’t work. The combination is proven and well-understood.

Onconetix did not invent these drugs or their combination. Instead, the company formulated them together in a single daily tablet. The FDA approved ENTADFI based on the clinical evidence for both components. The advantage to the patient is simplicity: one pill instead of two. The advantage to Onconetix is that a branded combination can command a higher price than the sum of generic parts, and the combination is protected by patents that prevent generic substitution while those patents last.

The market for BPH is huge. Millions of men use these drugs. But the competitive position is weak: both finasteride and tadalafil are available as cheap generics and are often prescribed together off-label already. A doctor or patient switching to the branded combination must see value in the single-pill form sufficient to justify higher cost. Insurance companies prefer cheap generics. The drug will generate revenue, but the moat — any durable competitive advantage — is thin. As soon as the patents expire, generic versions of the combination will emerge.

Revenue and commercialization

Onconetix is very early. Proclarix has no U.S. revenue yet; it is in partnership discussions and regulatory pathway development with LabCorp. The timeline is measured in months to a couple of years before the test is widely available. ENTADFI has been FDA-approved but is in early commercialization; initial sales are small.

The company is pre-revenue or minimally profitable. It exists on investor funding and the hope that Proclarix becomes a standard-of-care test and ENTADFI gains adoption. Both are plausible; neither is assured.

The moat, or lack thereof

Neither product has a strong moat. Proclarix’s value is real — it identifies significant disease better than the alternatives — but many other blood tests are in development for prostate cancer. The test is not a unique molecular signature; competitors will follow. The real moat, if any, is LabCorp’s distribution network and the test becoming standard in practice. But that is adoption and habit, not IP protection.

ENTADFI is a branded generic combination. The only moat is patent protection, and that expires. After patent loss, generic makers will offer identical pills at a fraction of the price. Then Onconetix will have no competitive advantage.

How to research Onconetix

The SEC filing (CIK 0001782107) describes the Proclarix partnership with LabCorp, the ENTADFI regulatory status, and the company’s cash position and burn rate. Clinical data for Proclarix is published in peer-reviewed literature; the clinical evidence is strong for the use case. Earnings calls describe commercialization progress. Watch for: Proclarix’s launch timeline and adoption by LabCorp’s network, ENTADFI’s initial sales and prescription trends, and any new product announcements. The company’s value rides on these two products and whether they can gain market traction and scale.